<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185796</url>
  </required_header>
  <id_info>
    <org_study_id>BMT168</org_study_id>
    <secondary_id>95130</secondary_id>
    <secondary_id>BMT168</secondary_id>
    <secondary_id>13680</secondary_id>
    <nct_id>NCT00185796</nct_id>
  </id_info>
  <brief_title>TLI &amp; ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD</brief_title>
  <official_title>Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly&#xD;
      patients with advanced stage MDS and MPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total Lymphoid Irradiation and Anti-Thymocyte Globulin as Conditioning for Non-Myeloablative&#xD;
      Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myelodysplastic Syndromes&#xD;
      and Myeloproliferative Disorders (except CML). To evaluate the feasibility and safety of&#xD;
      TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid&#xD;
      conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To improve survival outcome for selected patients with advanced stages of MDS and MPD with non-myeloablative allogeneic HCT from related and unrelated donors.</measure>
    <time_frame>7/15/2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly patients or those with co-morbid conditions that preclude myeloablative transplantation for advanced stage MDS and MPD.</measure>
    <time_frame>7/15/2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate myeloid and platelet engraftment.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of acute and chronic GVHD.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of primary and secondary graft failure.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the rate of relapse, survival and event-free survival.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate if DLI can be used safely in patients with mixed chimerism.</measure>
    <time_frame>7/15/2017</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Blood Cancer</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Lymphoid Irradiation (TLI)</intervention_name>
    <description>TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1</description>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anti-Thymocyte Globulin as Conditioning (ATG)</intervention_name>
    <description>Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.</description>
    <arm_group_label>TLI/ATG conditioning</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        GENERAL INCLUSION CRITERIA&#xD;
&#xD;
          -  General inclusion criteria must include at least one of the following:&#xD;
&#xD;
               -  Patients aged &gt; 49 and &lt; 75 years with MDS or MPD&#xD;
&#xD;
               -  Patients aged &lt; 49 years at high risk for regimen related toxicity using standard&#xD;
                  high dose regimens. Factors considered high risk include pre-existing conditions&#xD;
                  such as a chronic disease affecting kidneys, liver, lungs, or heart.&#xD;
&#xD;
               -  Patients with secondary MDS following a prior autologous transplant.&#xD;
&#xD;
          -  An HLA-identical related or an HLA-matched unrelated donor is available. ABO&#xD;
             incompatibility is acceptable.&#xD;
&#xD;
          -  A signed informed consent form.&#xD;
&#xD;
        MYELODYSPLASTIC SYNDROME CRITERIA&#xD;
&#xD;
          -  Diagnosis of MDS classifiable by the FAB system as refractory anemia (RA), refractory&#xD;
             anemia with ringed sideroblasts (RARS), chronic myelomonocytic leukemia (CMML),&#xD;
             refractory anemia with excess blasts (RAEB), and MDS transformed to acute leukemia.&#xD;
&#xD;
          -  Patients with advanced MDS must be cytoreduced to &lt; 10% marrow blasts prior to&#xD;
             receiving conditioning with TLI/ATG. Less than 10% marrow blasts must be documented by&#xD;
             marrow examination within 1 month of starting conditioning. The cytoreductive regimen&#xD;
             will be determined by referring centers.&#xD;
&#xD;
          -  Patients with evolution to AML are required to be in a complete remission as defined&#xD;
             by a blast count of less than 5% in a marrow aspirate with adequate cellularity.&#xD;
             Presence of residual dysplastic features following cytoreductive therapy is&#xD;
             acceptable.&#xD;
&#xD;
          -  All patients with high risk disease, for example &quot;intermediate-2&quot; or &quot;high risk&quot;&#xD;
             disease by the IPSS score. Other selected patients with a lower IPSS score may be&#xD;
             considered but only after discussion with the BMT attending physicians, as a group,&#xD;
             and the PI of the study.&#xD;
&#xD;
        MYELOPROLIFERATIVE DISORDERS&#xD;
&#xD;
          -  Myeloproliferative disorders to be included:&#xD;
&#xD;
               -  Philadelphia chromosome-negative CML.&#xD;
&#xD;
               -  Patients with polycythemia vera with persistent thrombotic or hemorrhagic&#xD;
                  complications despite conventional therapy, or who have progressed to&#xD;
                  post-polycythemic marrow fibrosis.&#xD;
&#xD;
               -  Patients with essential thrombocythemia with persistent thrombotic or hemorrhagic&#xD;
                  complications despite conventional therapy, or who have progressed to&#xD;
                  myelofibrosis.&#xD;
&#xD;
               -  Patients with agnogenic myeloid metaplasia with high risk disease, for example&#xD;
                  &quot;intermediate&quot; or &quot;high risk&quot; according to the Lille Scoring System.&#xD;
&#xD;
          -  Patients must be cytoreduced to &lt; 10% marrow blasts. Less than 10% marrow blasts must&#xD;
             be documented by marrow examination within 1 month of initiation of TLI/ATG. The&#xD;
             cytoreductive regimen will be determined by referring centers.&#xD;
&#xD;
          -  Patients with evolution to AML are required to be in a complete remission as defined&#xD;
             by a blast count of less than 5% in a marrow aspirate with adequate cellularity.&#xD;
             Presence of residual dysplastic features following cytoreductive therapy is&#xD;
             acceptable.&#xD;
&#xD;
        INCLUSION CRITERIA - RELATED DONORS&#xD;
&#xD;
          -  Related to the patient and is genotypically or phenotypically HLA-identical.&#xD;
&#xD;
          -  Donor age &lt; 75 unless cleared by P.I&#xD;
&#xD;
          -  Capable of giving written, informed consent.&#xD;
&#xD;
          -  Donor must consent to PBSC mobilization with G-CSF and apheresis&#xD;
&#xD;
        INCLUSION CRITERIA - UNRELATED DONORS&#xD;
&#xD;
          -  Donors must be HLA-matched as defined by the following criteria:&#xD;
&#xD;
               -  Matched for HLA-DRB1 and DQB1 by high resolution typing.&#xD;
&#xD;
               -  Serologic match for all recognized HLA-A, HLA-B, and HLA-C antigens, and&#xD;
                  molecular match for at least 5 of 6 HLA-A, HLA-B, or HLA-C antigens by high&#xD;
                  resolution typing.&#xD;
&#xD;
          -  Donor must consent to PBSC mobilization with G-CSF and apheresis. Bone marrow&#xD;
             unrelated donors are not eligible for this protocol.&#xD;
&#xD;
        Exclusion Criteria:GENERAL EXCLUSION CRITERIA&#xD;
&#xD;
          -  Organ dysfunction as defined by the following:&#xD;
&#xD;
               -  Renal: Patients with a normal creatinine are eligible for study without the need&#xD;
                  for a 24 hr urine collection for creatinine clearance. Patients with an elevated&#xD;
                  creatinine require a 24 hr urine collection. If the creatinine clearance is &lt; 50&#xD;
                  ml/min patients will be determined for inclusion on a case by case basis.&#xD;
&#xD;
               -  Cardiac: Ejection fraction &lt; 40%, symptomatic congestive heart failure requiring&#xD;
                  therapy, poorly controlled cardiac arrythmias, or poorly controlled hypertension&#xD;
                  with inability to maintain a steady-state blood pressure of 150/90.&#xD;
&#xD;
               -  Pulmonary: Requirement for supplemental oxygen administration, or pulmonary&#xD;
                  function testing showing (1) DLCO &lt; 50% of predicted, (2) TLC &lt; 30%, or (3) FEV1&#xD;
                  &lt; 30%.&#xD;
&#xD;
               -  Hepatic: Patients with clinical or laboratory evidence of liver disease would be&#xD;
                  evaluated for the cause of liver disease, its clinical severity in terms of liver&#xD;
                  function and degree of portal hypertension. Patients will be excluded if they are&#xD;
                  found to have fulminant liver failure, cirrhosis if the liver with evidence of&#xD;
                  portal hypertension, alcoholic hepatitis, esophageal varices, a history of&#xD;
                  bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic&#xD;
                  synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites&#xD;
                  related to portal hypertension, bacterial or fungal liver abscess. Biliary&#xD;
                  obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dl, and&#xD;
                  symptomatic biliary disease.&#xD;
&#xD;
          -  Bone marrow documenting blast count &gt;=10%.&#xD;
&#xD;
          -  Presence of active of non-hematologic malignancy (except localized non-melanoma skin&#xD;
             malignancies) or hematologic malignancy other than MDS or MPD as listed in inclusion&#xD;
             criteria.&#xD;
&#xD;
          -  Active CNS involvement of disease.&#xD;
&#xD;
          -  Karnofsky performance score &lt;= 60% or Lansky-Play Performance score &lt;50 for pediatric&#xD;
             patients.&#xD;
&#xD;
          -  Life expectancy severely limited by diseases other than malignancy.&#xD;
&#xD;
          -  Fungal infections with radiological progression despite with an amphotericin product&#xD;
             or active triazole for &gt; 1 month.&#xD;
&#xD;
          -  Active bacterial infection.&#xD;
&#xD;
          -  Patients of fertile age who refuse contraception for a twelve month period&#xD;
             post-transplant.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Severe psychological illness.&#xD;
&#xD;
        EXCLUSION CRITERIA - RELATED DONORS&#xD;
&#xD;
          -  Identical twin&#xD;
&#xD;
          -  Any contra-indication to the administration of subcutaneous G-CSF at a dose of&#xD;
             16mg/kg/d for five consecutive days&#xD;
&#xD;
          -  Serious medical or psychological illness&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Prior malignancy within the preceding five years, with the exception of non-melanoma&#xD;
             skin cancers.&#xD;
&#xD;
          -  HIV seropositivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>49 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 16, 2015</last_update_submitted>
  <last_update_submitted_qc>March 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Lowsky</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

